Neuroprotective Peptides: An Overview of the Research Landscape

Few words in neuroscience are used as loosely as “neuroprotective.” In its strict sense it means an intervention that reduces the loss of neurons or their function after an insult, stroke, trauma, neurodegenerative disease, measured with hard endpoints such as infarct volume, cell counts or validated functional scales. In practice the term is applied to anything that raises a growth factor, lowers an inflammatory marker or improves a behavioral score in a rodent. Peptides figure prominently in this field because many endogenous signals that regulate neuronal survival are themselves peptides, and because short synthetic sequences can be designed to mimic or stabilize them. This note surveys the main peptide classes under study, what each has shown in models and in people, and why the record of translation is sobering.

What “neuroprotective” has to mean

A useful discipline is to separate three layers of evidence. The first is mechanism: does the compound change a pathway plausibly linked to neuronal survival, neurotrophin expression, inflammatory signaling, mitochondrial function? The second is preclinical outcome: in an animal injury model, does it reduce lesion size or preserve function? The third is clinical outcome: in a randomized human trial, does it change a disability score or slow decline? Most peptides discussed here have strong evidence at the first layer, thinner evidence at the second, and, where tested, disappointing evidence at the third. Keeping the layers distinct is the single most useful habit when reading this literature.

Melanocortin-derived peptides

The best-developed example in the research-peptide space is Semax, a stabilized fragment of ACTH(4-10). Its mechanistic evidence is solid for a peptide of its size: intranasal administration in rats increased BDNF and TrkB expression in hippocampus within hours,¹ and transcriptomic and proteomic studies in rat ischemia–reperfusion models describe suppressed inflammatory mediators and expression profiles consistent with protection.² Semax is a registered stroke medicine in Russia, but the clinical trials behind that registration were small and largely unblinded, and no independent systematic review exists. The compound is covered in detail in Semax: A Review of Neuropeptide Research; its evidence sits firmly at the mechanism layer with a contested clinical layer above it.

Incretin peptides and the brain

An unexpected entrant to neuroprotection research is the GLP-1 receptor agonist class, developed for diabetes and obesity. GLP-1 receptors are expressed in brain, and preclinical work in Parkinson’s models suggested that agonists reduced dopaminergic neuron loss. This led to one of the more rigorous tests any “neuroprotective peptide” has received. In 2017, Athauda and colleagues reported a randomized, placebo-controlled trial of once-weekly exenatide in Parkinson’s disease: patients on exenatide had better off-medication motor scores at 60 weeks than those on placebo.³ The result generated considerable optimism.

The phase 3 follow-up did not confirm it. Exenatide-PD3, a UK multicenter trial in nearly 200 participants over 96 weeks, found no difference from placebo on the primary motor outcome.⁴ The sequence, positive mechanism, positive rodent data, positive phase 2, negative phase 3, is the archetypal trajectory of neuroprotection research and worth remembering when reading any earlier-stage claim. Incretin biology more broadly is covered in What Are GLP-1 Peptides?.

The history of neuroprotection is a history of compounds that worked in rats and were tested honestly in humans.

Neurotrophin mimetics and modulators

BDNF itself is a poor drug candidate, too large, too short-lived, unable to cross the blood–brain barrier, so much of the field has looked for small molecules or peptides that activate its receptor, TrkB, or increase its expression. The flavonoid 7,8-dihydroxyflavone was reported in 2010 to act as a selective TrkB agonist with neurotrophic activity in cultured neurons and in mouse injury models,⁵ and it remains a widely used research tool. Peptides that raise BDNF expression, including Semax, belong in this category mechanistically. The signaling biology and its complications, including the opposing effects of pro-BDNF through the p75 receptor, are discussed in BDNF and Neurotrophic Signaling in Peptide Research.

A cautionary case is davunetide (NAP), an eight-amino-acid fragment of activity-dependent neuroprotective protein. It stabilized microtubules and protected neurons in multiple preclinical models, and advanced to a phase 2/3 trial in progressive supranuclear palsy. Boxer and colleagues reported in 2014 that davunetide had no effect on either primary endpoint over 52 weeks.⁶ It is one of the cleanest examples of a peptide with excellent mechanistic and preclinical credentials failing at the clinical layer.

Peptide mixtures: the Cerebrolysin case

Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides and amino acids, registered in several countries for stroke and dementia and marketed on a neurotrophic rationale. It matters here because it has been evaluated by Cochrane. The 2020 review, pooling randomized trials in acute ischemic stroke, found no evidence of benefit on death or disability and noted an increase in serious adverse events in treated groups, with moderate-quality evidence.⁷ The review is a template for how a neuropeptide product’s clinical claims look once subjected to systematic appraisal, and the contrast with the manufacturer literature is instructive.

Mitochondrial-derived peptides and the NAD+ axis

A newer class comes from within the mitochondrion. Short open reading frames in mitochondrial DNA encode peptides, humanin, MOTS-c and the SHLPs, that appear to regulate cellular stress responses and metabolism, and several have been studied for protection against neuronal injury in vitro and in rodents. The evidence is almost entirely preclinical and is reviewed in MOTS-c: A Mitochondrial-Derived Peptide in Metabolic Research and Mitochondrial-Derived Peptides.

These peptides sit on top of a more fundamental axis: nicotinamide adenine dinucleotide. NAD+ is the cofactor for sirtuins and PARPs and a substrate for the NADase SARM1, which executes axon degeneration after injury. Lautrup, Fang and colleagues reviewed in 2019 how NAD+ levels decline in the aging brain and in neurodegenerative models, and how restoring them improves mitochondrial function, DNA repair and neuronal survival in animals.⁸ NAD+ is not a peptide, but it is the biochemical ground on which much peptide neuroprotection research is conducted, and laboratories studying the two together are common. Background is in What Is NAD+?.

Where each class stands

Class	Example	Mechanism evidence	Preclinical outcome	Randomized clinical outcome
Melanocortin fragments	Semax	BDNF/TrkB induction; anti-inflammatory transcripts1,2	Molecular endpoints in rat ischemia	Russian trials, not independently reviewed
Incretin agonists	Exenatide	GLP-1R signaling in neurons	Reduced neuron loss in PD models	Positive phase 2;3 negative phase 34
Neurotrophin mimetics	7,8-DHF; davunetide	TrkB agonism;5 microtubule stabilization	Positive in multiple models	Davunetide negative in PSP6
Peptide mixtures	Cerebrolysin	Proposed neurotrophic activity	Variable	No benefit in Cochrane review7
Mitochondrial peptides	MOTS-c, humanin	Metabolic stress signaling	Early-stage	None
NAD+ axis	NAD+ and precursors	Sirtuin, PARP, SARM1 biology8	Positive in aging and injury models	Small trials, no disease-modifying result

What researchers can reasonably do

For laboratory work, the peptides in this note are useful as probes of specific pathways: Semax for neurotrophin transcription, GLP-1 agonists for incretin receptor signaling in neural tissue, mitochondrial peptides for stress-response biology, NAD+ for the energy and repair axis. The value is in the mechanism, and the honest framing is that mechanism is where the evidence lives. Wednesday lists Semax and NAD+ for research; certificates of analysis for both are in the COA library. What none of the research-grade materials carry is any of the clinical narrative, positive or negative, attached to the pharmaceutical products discussed above.

Frequently asked questions

What are neuroprotective peptides?

They are peptides studied for their capacity to limit neuronal injury or death. The main classes are melanocortin-derived fragments such as Semax, incretin receptor agonists, neurotrophin mimetics, mitochondrial-derived peptides, and brain-derived peptide mixtures. Most evidence is mechanistic or preclinical.

Has any peptide been proven neuroprotective in humans?

Not by the standard of a positive, independently replicated phase 3 trial. The GLP-1 agonist exenatide had a positive phase 2 trial in Parkinson’s disease but a negative phase 3. Davunetide failed in progressive supranuclear palsy. Cerebrolysin showed no benefit in a Cochrane review of stroke trials.

Is Semax neuroprotective?

In rat models, Semax increases BDNF and TrkB expression and reduces inflammatory gene expression after ischemia. It is registered for stroke in Russia, but those trials were not independently reviewed. The evidence supports a mechanism; it does not establish clinical neuroprotection.

How does NAD+ relate to neuroprotection?

NAD+ is the cofactor for sirtuins and PARPs and the substrate for SARM1, an enzyme that drives axon degeneration. Brain NAD+ declines with age and in neurodegenerative models, and restoring it improves neuronal survival in animals. It is a shared axis under much peptide neuroprotection research.

Why do neuroprotective drugs fail in clinical trials?

Animal models use young subjects, controlled injuries and precise timing that human disease lacks. Outcome measures differ, and rodent brains differ from human ones in size, white-matter proportion and repair capacity. The result is a long record of compounds that worked in rats and not in people.

References & further reading

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. doi:10.1016/j.brainres.2006.07.108 / PMID 16996037
2. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia–reperfusion. Int J Mol Sci. 2021;22(12):6179. doi:10.3390/ijms22126179
3. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675. doi:10.1016/S0140-6736(17)31585-4 / PMID 28781108
4. Vijiaratnam N, Girges C, Auld G, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405(10479):627–636. doi:10.1016/S0140-6736(24)02808-3
5. Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A. 2010;107(6):2687–2692. doi:10.1073/pnas.0913572107 / PMID 20133810
6. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–685. doi:10.1016/S1474-4422(14)70088-2 / PMID 24873720
7. Ziganshina LE, Abakumova T, Hoyle CHV. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2020;7:CD007026. doi:10.1002/14651858.CD007026.pub6 / PMID 32662068
8. Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metab. 2019;30(4):630–655. doi:10.1016/j.cmet.2019.09.001 / PMID 31577933